A small San Diego biotech has identified a drug that appears to prevent several subtypes of the human papillomavirus (HPV) from replicating—including the two HPV subtypes that cause 70 percent of all cases of cervical cancer.

“It’s early, so we shouldn’t hype it too much. But the antiviral studies look pretty good,” said Karl Hostetler, an emeritus professor of medicine at UC San Diego, and the founding CEO of Hera Therapeutics. The two-year-old startup has been incubating in the Janssen Labs life sciences accelerator in San Diego.

READ FULL ARTICLE Curated publisher From Xconomy